Passage Bio, Inc. Common Stock (PASG) is a publicly traded Healthcare sector company. As of May 21, 2026, PASG trades at $5.00 with a market cap of $16.42M and a P/E ratio of -0.37. PASG moved +5.31% today. Year to date, PASG is -67.72%; over the trailing twelve months it is -17.25%. Its 52-week range spans $3.94 to $26.60. Analyst consensus is neutral with an average price target of $11.75. Rallies surfaces PASG's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Passage Bio’s Trial Shows 64% Brain Atrophy Reduction, FDA Demands RCT: Passage Bio’s Phase 1/2 upliFT-D trial of PBFT02 in FTD-GRN showed a 64% reduction in whole brain atrophy and a 54% decrease in frontotemporal cortex atrophy at 12 months versus controls. Plasma NfL stabilized with a 1.0 pg/mL drop versus a 13.5 pg/mL rise, while CSF progranulin exceeded 22 ng/mL.
| Metric | Value |
|---|---|
| Price | $5.00 |
| Market Cap | $16.42M |
| P/E Ratio | -0.37 |
| EPS | $-14.35 |
| Dividend Yield | 0.00% |
| 52-Week High | $26.60 |
| 52-Week Low | $3.94 |
| Volume | 162 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-45.52M |
| Gross Margin | 0.00% |
5 analysts cover PASG: 0 strong buy, 1 buy, 4 hold, 0 sell, 0 strong sell. Consensus rating is neutral. Average price target: $11.75.